France hits Roche and Novartis with €444 million fine
France’s Competition Authority has fined Roche, Novartis and Genentech a total of €444 million for abusing their collective dominance by preventing the entry of a cheaper eye treatment drug into the French market.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.